TY - JOUR
T1 - Multiplex ligation-dependent probe amplification versus karyotyping in prenatal diagnosis
T2 - The M.A.K.E. study
AU - Boormans, Elisabeth M.A.
AU - Birnie, Erwin
AU - Wildschut, Hajo I.
AU - Schuring-Blom, Heleen G.
AU - Oepkes, Dick
AU - van Oppen, Carla A.C.
AU - Nijhuis, Jan G.
AU - Macville, Merryn V.E.
AU - Kooper, Angelique J.A.
AU - Huijsdens, Karin
AU - Hoffer, Mariëtte V.J.
AU - Go, Attie
AU - Creemers, Johan
AU - Bhola, Shama L.
AU - Bilardo, Katia M.
AU - Suijkerbuijk, Ron
AU - Bouman, Katelijne
AU - Galjaard, Robert Jan H.
AU - Bonsel, Gouke J.
AU - van Lith, Jan M.M.
N1 - Funding Information:
This study is funded by Zon-MW grant (945-27-045).
PY - 2008
Y1 - 2008
N2 - Background: In the past 30 years karyotyping was the gold standard for prenatal diagnosis of chromosomal aberrations in the fetus. Traditional karyotyping (TKT) has a high accuracy and reliability. However, it is labor intensive, the results take 14-21 days, the costs are high and unwanted findings such as abnormalities with unknown clinical relevance are not uncommon. These disadvantages challenged the practice of karyotyping. Multiplex ligation-dependent probe amplification (MLPA) is a new molecular genetic technique in prenatal diagnosis. Previous preclinical evidence suggests equivalence of MLPA and traditional karyotyping (TKT) regarding test performance. Methods/Design: The proposed study is a multicentre diagnostic substitute study among pregnant women, who choose to have amniocentesis for the indication advanced maternal age and/or increased risk following prenatal screening test. In all subjects, both MLPA and karyotyping will be performed on the amniotic fluid sample. The primary outcome is diagnostic accuracy. Secondary outcomes will be maternal quality of life, women's preferences and costs. Analysis will be intention to treat and per protocol analysis. Quality of life analysis will be carried out within the study population. The study aims to include 4500 women. Discussion: The study results are expected to help decide whether MLPA can replace traditional karyotyping for 'low-risk' pregnancies in terms of diagnostic accuracy, quality of life and women's preferences. This will be the first clinical study to report on all relevant aspects of the potential replacement.
AB - Background: In the past 30 years karyotyping was the gold standard for prenatal diagnosis of chromosomal aberrations in the fetus. Traditional karyotyping (TKT) has a high accuracy and reliability. However, it is labor intensive, the results take 14-21 days, the costs are high and unwanted findings such as abnormalities with unknown clinical relevance are not uncommon. These disadvantages challenged the practice of karyotyping. Multiplex ligation-dependent probe amplification (MLPA) is a new molecular genetic technique in prenatal diagnosis. Previous preclinical evidence suggests equivalence of MLPA and traditional karyotyping (TKT) regarding test performance. Methods/Design: The proposed study is a multicentre diagnostic substitute study among pregnant women, who choose to have amniocentesis for the indication advanced maternal age and/or increased risk following prenatal screening test. In all subjects, both MLPA and karyotyping will be performed on the amniotic fluid sample. The primary outcome is diagnostic accuracy. Secondary outcomes will be maternal quality of life, women's preferences and costs. Analysis will be intention to treat and per protocol analysis. Quality of life analysis will be carried out within the study population. The study aims to include 4500 women. Discussion: The study results are expected to help decide whether MLPA can replace traditional karyotyping for 'low-risk' pregnancies in terms of diagnostic accuracy, quality of life and women's preferences. This will be the first clinical study to report on all relevant aspects of the potential replacement.
UR - http://www.scopus.com/inward/record.url?scp=44649196405&partnerID=8YFLogxK
U2 - 10.1186/1471-2393-8-18
DO - 10.1186/1471-2393-8-18
M3 - Article
C2 - 18492228
AN - SCOPUS:44649196405
SN - 1471-2393
VL - 8
JO - BMC Pregnancy and Childbirth
JF - BMC Pregnancy and Childbirth
M1 - 18
ER -